These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29398960)

  • 1.
    Naik C; Basu S
    World J Nucl Med; 2018; 17(1):12-20. PubMed ID: 29398960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
    Basu S; Ranade R; Thapa P
    World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial clinical evaluation of indigenous
    Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
    World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of
    Basu S; Parghane RV; Naik C
    World J Nucl Med; 2020; 19(3):205-210. PubMed ID: 33354174
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Thapa P; Parghane R; Basu S
    World J Nucl Med; 2017; 16(3):223-228. PubMed ID: 28670182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Sabet A; Ezziddin K; Pape UF; Reichman K; Haslerud T; Ahmadzadehfar H; Biersack HJ; Nagarajah J; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):505-10. PubMed ID: 24196919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of renal filtration fraction evaluation of renal artery stenting for atherosclerotic renal artery stenosis treatment].
    Feng QC; Li X; Luan JY; Wang CM; Li TR
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Feb; 49(1):158-63. PubMed ID: 28203024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Pawlak D; Hubalewska-Dydejczyk A; Mikołajczak R
    Endokrynol Pol; 2013; 64(1):13-20. PubMed ID: 23450442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Function Assessment During Peptide Receptor Radionuclide Therapy.
    Erbas B; Tuncel M
    Semin Nucl Med; 2016 Sep; 46(5):462-78. PubMed ID: 27553471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-arterial PRRT with Lu-177 DOTATATE in Liver-dominant Metastatic Neuroendocrine Tumors: Early Assessment of Efficacy and Toxicity.
    Puranik AD; Rangarajan V; Shetty NS; Gala K; Kulkarni S; Mohite A; Marotkar M; Gawale Y; Dev ID; Shrikhande SV; Chaudhari V; Bhandare M; Agrawal A; Shah S; Purandare NC; Ghosh S; Choudhury S
    Indian J Nucl Med; 2024; 39(2):71-76. PubMed ID: 38989301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor saturation after administration of high peptide amounts of [
    Siebinga H; Veerman CHAM; de Wit-van der Veen L; Stokkel MPM; Hendrikx JJMA; Aalbersberg EA
    EJNMMI Res; 2022 Dec; 12(1):74. PubMed ID: 36515683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival.
    Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J
    Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of changes in radionuclide measures of effective renal plasma flow and glomerular filtration rate in spinal cord injury patients.
    Jacobson AF; Britell C; Little JW
    J Am Paraplegia Soc; 1994 Jan; 17(1):15-9. PubMed ID: 8169601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.